

THRIVE

Important Announcements

- 50% enrollment goal met in December, ahead of schedule
- Data Safety & Monitoring Board (DSMB) approved continuation of the feasibility study

Enrollment & Randomization Tracking

258

Patients Enrolled

204

Patients Randomized

Operational Updates

Protocol & Enrollment

- Collecting lessons learned to share with full-scale sites
- Feasibility protocol under review for publication at [BMJ Open](#)
- Clinician Education Resources available on [MPOG website](#)

Information Systems

- Developing automated operational metrics and reports
- thrivetrial.org informational website
- Continued refinement of data collection processes

Stakeholder Engagement

- Learning to THRIVE: [Understanding and Sharing Research Findings](#) - Jan. 24th meeting
- Patient End of Study survey under review, incorporating patient partner feedback
- [Patient Partner Panel feedback request form](#)

Timeline Update

The next major timepoints for the study include the end of feasibility and the

beginning of full-scale.



Image credit [Slidesgo](#) and [Freepik](#)

Emerging & Relevant Literature



Ongoing trial comparing various anesthetic techniques on outcomes related to cancer

The [Volatile Anaesthesia and Perioperative Outcomes Related to Cancer \(VAPOR-C\) trial](#) is a large, international, randomized clinical trial of inhalational volatile or intravenous propofol anesthesia (TIVA) and intravenous lidocaine/placebo to improve disease free survival after surgery for colorectal cancer and lung cancer.

Our THRIVE trial was designed in part as a complement to VAPOR-C, in order to help contribute to the existing body of literature on TIVA.

Suggestion Box

Are our newsletters informative?
Could they be better?

Tell us how we're doing!

[Complete the Google Form here.](#)



Funded by
Contract 2020C3-21106

